BSARSTNeoAgVax

BSARSTNeoAgVax is a SARS-CoV-2 B cell epitope-guided neoantigen peptide/mRNA cancer nanovaccine. It is designed to enhance tumor-specific CD4 and CD8 T cell immunity by promoting B cell-mediated antigen presentation. The vaccine achieves this by cross-linking with the B cell receptor, leading to increased tumor-specific follicular/nonfollicular CD4 T cells and enhanced B cell-dependent tumor-specific CD8 T cell immunity. Studies have shown that BSARSTNeoAgVax achieved superior efficacy in melanoma, pancreatic, and breast cancer models compared to current neoantigen vaccines, suggesting its potential as a universal platform for various cancer types.